| Literature DB >> 31140760 |
Chun-Qiang Lu1, Weiwei Xu1, Chu-Hui Zeng1, Lu-Yao Ge2, Yuan-Cheng Wang1, Xiang-Pan Meng1, Qian Yu1, Di Wu1, Shenghong Ju1.
Abstract
INTRODUCTION: Patients under chronic obstructive pulmonary disease (COPD) has been reported to be associated with a higher prevalence of cognitive impairment (CI). However, it is still largely unknown whether the aberrant resting-state spontaneous neuronal activity pattern reflected by the amplitude of low-frequency fluctuation (ALFF) analysis will be associated with the CI in COPD patients. MATERIALS: A total of 28 COPD patients and 26 healthy controls were enrolled in this study. Of all the subjects, structural and functional MRI data, spirometry tests performance and neuropsychological assessments of different cognitive domains were collected. Voxel-based two-sample t tests were used to detect brain regions showing differences in the ALFF value between COPD patients and healthy controls. An additional fMRI runs with supplementary oxygen delivery were employed to explore the impact of elevated partial pressure of oxygen (PaO2 ) or moderate hyperoxia on ALFF in COPD patients and healthy controls respectively.Entities:
Keywords: ALFF; Basal ganglia; COPD; brain; cognitive impairment; rs-fMRI
Mesh:
Year: 2019 PMID: 31140760 PMCID: PMC6625472 DOI: 10.1002/brb3.1336
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Clinical profile of COPD patients and controls
| COPD patients ( | Controls ( |
| |
|---|---|---|---|
| Age (years) | 63.12 ± 5.3 | 61.68 ± 4.63 | 0.335 |
| Sex (m/f) | 26/0 | 22/0 | NA |
| Years of education | 9.73 ± 2.20 | 10.41 ± 2.26 | 0.299 |
| Disease duration | 9.63 ± 7.81 | NA | NA |
| COPD staging ( | NA | NA | |
| Very mild (FEV1%pred ≥ 80) | 2 | NA | NA |
| Moderate (FEV1%pred 50–79) | 7 | NA | NA |
| Severe (FEV1%pred 30–49) | 9 | NA | NA |
| Very severe (FEV1%pred < 30) | 8 | NA | NA |
| Smoking (y/n) | 22/4 | 11/11 | 0.01 |
| Smoking (Pack‐years) | 35.20 ± 24.04 | 14.64 ± 16.93 | 0.002 |
| SaO2 (%) | 94.70 ± 3.46 | 97.64 ± 1.13 | <0.001 |
| Spirometry | |||
| FVC%pred | 67.34 ± 21.95 | 100.32 ± 10.55 | <0.001 |
| FEV1%pred | 48.00 ± 25.16 | 101.24 ± 14.06 | <0.001 |
| FEV1/FVC (%) | 51.11 ± 14.57 | 79.41 ± 6.34 | <0.001 |
| Blood gas analysis | |||
| PaO2 (%) | 82.55 ± 11.90 | NA | NA |
| PaCO2 (%) | 38.29 ± 5.26 | NA | NA |
| WMC rating score | |||
| White matter | 1 (0–2) | 1 (0–2) | 0.009 |
| Basal ganglia | 0.5 (0–2) | 0 (0–2) | 0.017 |
| Whole brain | 2 (0–4) | 1 (0–4) | 0.002 |
| Neuropsychological tests | |||
| MMSE | 26.15 ± 1.51 | 27.81 ± 1.37 | <0.001 |
| MoCA | 21.17 ± 3.86 | 24.09 ± 2.65 | 0.004 |
| CFT recognition | 34.54 ± 3.22 | 35.36 ± 1.29 | 0.267 |
| CFT‐delayed recall (20 min) | 13.88 ± 6.05 | 16.09 ± 7.00 | 0.247 |
| Task time for CFT recognition | 198.35 ± 56.92 | 153.73 ± 53.97 | 0.008 |
| AVLT | 14.12 ± 3.38 | 14.45 ± 3.51 | 0.736 |
| AVLT‐delayed recall (20 min) | 7.77 ± 4.75 | 9.63 ± 3.32 | 0.114 |
| Forward DST | 13.54 ± 2.61 | 14.00 ± 2.02 | 0.503 |
| Reverse DST | 6.84 ± 1.99 | 8.23 ± 1.41 | 0.009 |
| DSST | 29.46 ± 9.72 | 38.31 ± 10.30 | 0.004 |
| TMT‐A | 62.71 ± 18.04 | 52.50 ± 14.92 | 0.018 |
| TMT‐B | 167.23 ± 49.10 | 135.40 ± 29.12 | 0.011 |
Data were presented as mean ± SD or median (range).
Abbreviations: SaO2, Oxygen Saturation of Arterial Blood; WMC, White matter change; FVC, Forced Vital Capacity; FEV1, Forced Expiratory Volume in the first second; FVC%pred, ratio of FVC to predicted FVC; FEV1%pred, ratio of FEV1 to predicted FEV1; PaO2, Partial Pressure of Oxygen; PaCO2, Partial Pressure of Carbon Dioxide; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment; CFT, Complex Figure Test; AVLT, Auditory Verbal Learning Test; DST, Digit Span Test; DSST, Digit Symbol Substitution Test; TMT‐A, Trail‐making test‐A; TMT‐B, Trail‐making test‐B.
Total gray matter and white matter volume
| COPD | Control |
| |
|---|---|---|---|
| Total GM volume | 0.68 ± 0.048 | 0.71 ± 0.06 | 0.15 |
| Total WM volume | 0.52 ± 0.04 | 0.53 ± 0.05 | 0.42 |
| Brain Parenchyma | 1.21 ± 0.09 | 1.24 ± 0.11 | 0.25 |
GM, gray matter; WM, white matter.
Figure 1One‐sample t test s of ALFF map in COPD group and control group. T maps showing areas (Red color) in which ALFF value is significantly greater than whole brain mean are listed on the upper panel for COPD group, and bottom panel for Control group. Those areas mainly include the posterior cingulate cortex (PCC), precuneus (PCu), and medial prefrontal cortex (mPFC) which resembles the pattern of default‐mode network. No apparent difference was observed in the basic patterns of ALFF between the two groups
Figure 2Two‐sample t test of ALFF map between COPD group and control group. Decreased ALFF values were mainly located in the bilateral caudate, putamen, pallidum, and thalamus in COPD patients
Clusters of two‐sample t test of zALFF images between COPD patients and controls
| Cluster | Brain areas (AAL) | Voxel Size | Peak Coordinate | Area of peak voxel |
| ||
|---|---|---|---|---|---|---|---|
|
|
|
| |||||
| 1 | R Putamen | 90 | 14 | 14 | 3 | R Caudate | −5.22 |
| R Thalamus | 27 | ||||||
| R Caudate | 22 | ||||||
| R Pallidum | 10 | ||||||
| R Other areas (including WM) | 87 | ||||||
| 2 | L Putamen | 88 | −18 | 9 | 6 | R Putamen | −5.1 |
| L Pallidum | 10 | ||||||
| L Caudate | 7 | ||||||
| L Other areas (including WM) | 59 | ||||||
WM, white matter.
Figure 3Correlation analysis between aberrant ALFF value and clinical indexes. Aberrant ALFF value correlates with PaO2 in COPD group and correlates closely with FEV1%pred in all subjects (a and b, respectively). FEV1%pred correlates with task time for CFT recognition and MMSE as well (c and d, respectively)
Figure 4Change in ALFF in deep brain of COPD patients and healthy controls after supplementary oxygen inhalation. After oxygen delivery, the ALFF value of basal ganglia and right thalamus significantly increased in the control group (a), but not in the COPD group (b)